You are here: Home » Companies » News
Business Standard

Cipla will use Covid-19 bulk drugs inventory when demand rises

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

Cipla | Cipla Roche | Cipla results

Sohini Das 

Cipla, Cipla logo, Cipla headquarters
Photo: Reuters

Mumbai-based Cipla, which reported a one-time cost of Rs 200 crore for Covid-19 inventory and other charges in the March quarter (Q4), is sitting on inventory of the antibody cocktail drug from Roche, some bulk drug of remdesivir, and some stocks of molnupiravir. The Covid-19 portfolio contributed 5-6 per cent of Cipla’s turnover during peak Covid waves, the firm said.

Speaking to the media, Umang Vohra, managing director and global chief executive officer of Cipla, said most of the inventory is in the raw material side. “For example, the remdesivir bulk drug has a five-year shelf life. We can make remdesivir again whenever there is demand from hospitalised patients.” Vohra added that the bulk of the inventory is of the antibody cocktail from Roche – casrivimab and imdevimab – that had launched in India in May 2021.

Other drugs like Tocilizumab, a Roche drug, have alternative usages, and thus can be liquidated. The firm also has a tie-up to make Pfizer’s oral Covid-19 drug Paxlovid. Vohra said the firm will work to secure approval from the Indian drug regulator as well as regulators in other countries. “We will also keep some bulk drug ready. That way we can launch whenever there is demand for the drug,” Vohra said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, May 11 2022. 23:46 IST